• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

High IOP may not necessarily require treatment, results from new study suggests


Low-risk patients may be followed up without treatment

New data from a 20-year cohort, Ocular Hypertension Treatment Study (OHTS) revealed not all patients with high intraocular pressure (IOP) need pressure-reducing treatment to prevent glaucoma or vision-loss. The study appeared in the April 2021 issue of JAMA Ophthalmology.


The study analyzed the effects of different treatment options on over 1,000 participants with ocular hypertension. It also noted the severity of their condition over time.

For the study, which used 3 phases, the researchers collected data from participants who had primary open-angle glaucoma (POAG) in one or both eyes at 20 years of follow-up.


After adjustment for exposure time, the 20-year cumulative incidence of POAG among all participants was 46%. Among those who were only observed the incidence was 49%, and incidence was 42% in those who received medication.

Only one-fourth of the participants in the OHTS experienced visual field loss over long-term follow-up and years of treatment.

”These findings provide evidence to support better decision-making by patients in collaboration with their doctors,” says David Friedman, MD, PhD, MPH of Massachusetts Eye and Ear and Harvard Medical School, in Boston, Massachusetts, in a statement. “The findings align with the group’s earlier findings that delaying treatment for those with high eye pressures, who would have been eligible for this study, does not dramatically affect long-term prognosis, and that patients have different risks based on factors that can be measured.”

OD weighs in

Optometry Times® asked Chief Optometric Editor Benjamin Casella, OD, FAAO, to weigh in on the study’s results. Dr. Casella says the study advances valuable information for ODs.

“Studies such as OHTS do well to provide guidance as to both sensitivity and specificity with regard to treating high IOP,” Casella says. “By this I mean it is of utmost importance to treat those who need treatment, but it is also important to know when to monitor without treatment to avoid unneeded burdens on the patient, such as cost.”

Related Videos
Jeffrey J. Walline, OD, PhD
Nate Lighthizer, OD, speaks on lasers in optometry at AAOpt 2023
Gleb Sukhovolskiy, OD
Justin Schweitzer, OD, FAAO, and Selina McGee, OD, FAAO, Dipl ABO, discuss their AAOpt presentation on the intersection of dry eye and glaucoma
© 2023 MJH Life Sciences

All rights reserved.